Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer

Information

  • Research Project
  • 9856191
  • ApplicationId
    9856191
  • Core Project Number
    R44CA217534
  • Full Project Number
    3R44CA217534-02S1
  • Serial Number
    217534
  • FOA Number
    PA-18-837
  • Sub Project Id
  • Project Start Date
    3/1/2019 - 5 years ago
  • Project End Date
    5/31/2020 - 4 years ago
  • Program Officer Name
    KURTZ, ANDREW J
  • Budget Start Date
    3/1/2019 - 5 years ago
  • Budget End Date
    5/31/2019 - 5 years ago
  • Fiscal Year
    2019
  • Support Year
    02
  • Suffix
    S1
  • Award Notice Date
    4/15/2019 - 5 years ago
Organizations

Supplement grant for R44CA217534: Nanoparticle-based targeted codelivery of siRNA and taxane to treat drug-resistant HER2+ breast cancer

Project Summary/Abstract This administrative supplement grant application focuses on optimizing the sterilization method and large-scale synthesis of the lead nanoconstruct PDX-001-TX (developed in the parent award, R44CA217534), and supporting NIH?s mission to encourage institutions to diversify their student and faculty populations in biomedical, clinical, behavioral, and social sciences. Manufacturability is key in evaluating the translational potential of a lead drug candidate. To this effort, we aim to optimize the sterilization protocol of our material to produce clean and safe material for future clinical use. We also plan to perform large-scale synthesis of our lead nanoconstruct and evaluate its physicochemical characteristics, therapeutic efficacy, and sterility. Results will provide important data towards an investigational new drug (IND) application to the FDA. PDX Pharmaceuticals LLC has selected one post-baccalaureate researcher to design and conduct experiments, under the guidance and mentorship of the PIs, to achieve these goals. The post-baccalaureate candidate is classified by NIH?s guidelines as an individual who comes from an economically disadvantaged background. Thus, this supplement award will provide the candidate the opportunity to receive training in biomedical research, enhance his business skills, increase his prospect of graduate school admission, and help him develop into a successful scientist.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    14938
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:14938\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    PDX PHARMACEUTICALS, LLC
  • Organization Department
  • Organization DUNS
    025852616
  • Organization City
    LAKE OSWEGO
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    970351401
  • Organization District
    UNITED STATES